Caribou Biosciences (CRBU) Net Equity Issued and Repurchased (2021 - 2026)

Caribou Biosciences (CRBU) has reported Net Equity Issued and Repurchased for 5 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $6.3 million (up 62.8% YoY), while the FY2025 annual figure was $4.1 million, down 73.21% from the prior year.
• Net Equity Issued and Repurchased declined to $2.2 million in Q1 2026 per CRBU's latest filing, from $4.1 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $11.3 million in Q1 2024 and bottomed at -$115000.0 in Q2 2023.
• Historically, Net Equity Issued and Repurchased has averaged $3.2 million across 4 years, with a median of $2.2 million in 2026.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased jumped 908.82% — and 2025, when it gained 5.36%.
• Caribou Biosciences' Net Equity Issued and Repurchased stood at -$1000.0 in 2023, then soared by 386400.0% to $3.9 million in 2024, then advanced by 5.36% to $4.1 million in 2025, then tumbled by 45.48% to $2.2 million in 2026.
• Business Quant data shows CRBU's Net Equity Issued and Repurchased at $2.2 million in Q1 2026, $4.1 million in Q4 2025, and $3.9 million in Q4 2024.